Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by multiple markers of immune response to SARS-CoV-2 antigens.
“Our Phase I results highlight the importance of our differentiated vaccine design, as they suggest VXA-CoV2-1 could have broad activity against existing and future coronavirus strains. These results are timely, as we are seeing the emergence of new variants less responsive to first generation vaccines, thus making potential cross-reactivity another important advantage of next-generation vaccines,” said Andrei Floroiu, Vaxart’s Chief Executive Officer.
Vaxart’s scientists recognized early the risk of variants of SARS-CoV-2 emerging and they designed a vaccine with the potential to be protective not only against the prevalent strain, but also against emerging mutations of the Spike (S) protein, by including both the S and N proteins. Virtually all other COVID-19 vaccines include just the S protein.
“These results, together with recent data from our peers, further raise our confidence in the success of VXA-CoV2-1 and the broad potential of our platform,” continued Floroiu.
“We previously showed that our oral tablet vaccine technology worked to protect against flu – another airborne virus – as well as the leading injectable, but through a different mechanism, in a Phase II trial sponsored by BARDA. With COVID-19, we have now seen that many vaccine approaches— mRNA, protein, and viral vector, including three adenovirus vaccines – are protective, and that all available positive COVID-19 hamster challenge studies such as ours have translated into protection against COVID-19 in human trials,” Floroiu said.
“These clinical data further differentiate our COVID-19 vaccine and enable us to meaningfully advance discussions with healthcare officials in the U.S. and around the world about how Vaxart may be able to help them fight back against COVID-19 with a transformative solution – a room-temperature stable oral vaccine that is not only easier to distribute and administer, but may also be more broadly protective,” Floroiu added.
- Ecuador reports new cases of the UK COVID-19 variant
- Taiwan reports 1st hantavirus case of the year
- Iowa confirms three cases of the UK COVID-19 variant
- South Africa reports another human rabies death
- SARS-CoV-2 501Y.V2 lineage may be predominant throughout South Africa
- Alaska reports 1st UK COVID-19 variant case in Anchorage resident
- Europe authorizes AstraZeneca’s COVID-19 vaccine, 3rd vaccine to be approved